DE69232669D1 - Mit gp11b/iiia reaktive humane antikörper - Google Patents

Mit gp11b/iiia reaktive humane antikörper

Info

Publication number
DE69232669D1
DE69232669D1 DE69232669T DE69232669T DE69232669D1 DE 69232669 D1 DE69232669 D1 DE 69232669D1 DE 69232669 T DE69232669 T DE 69232669T DE 69232669 T DE69232669 T DE 69232669T DE 69232669 D1 DE69232669 D1 DE 69232669D1
Authority
DE
Germany
Prior art keywords
iiia
gp11b
human antibodies
reactive human
reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232669T
Other languages
English (en)
Other versions
DE69232669T2 (de
Inventor
Man Sung Co
Yun Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
PDL Biopharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Protein Design Labs Inc filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of DE69232669D1 publication Critical patent/DE69232669D1/de
Application granted granted Critical
Publication of DE69232669T2 publication Critical patent/DE69232669T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69232669T 1991-12-20 1992-12-15 Mit gp11b/iiia reaktive humane antikörper Expired - Fee Related DE69232669T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211191A 1991-12-20 1991-12-20
US89595292A 1992-06-09 1992-06-09
US94415992A 1992-09-11 1992-09-11
PCT/JP1992/001630 WO1993013133A1 (en) 1991-12-20 1992-12-15 HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa

Publications (2)

Publication Number Publication Date
DE69232669D1 true DE69232669D1 (de) 2002-08-08
DE69232669T2 DE69232669T2 (de) 2003-02-27

Family

ID=27420074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232669T Expired - Fee Related DE69232669T2 (de) 1991-12-20 1992-12-15 Mit gp11b/iiia reaktive humane antikörper

Country Status (10)

Country Link
EP (1) EP0619324B1 (de)
JP (1) JP2723671B2 (de)
KR (1) KR100240159B1 (de)
AT (1) ATE220100T1 (de)
AU (1) AU3095892A (de)
CA (1) CA2126182C (de)
DE (1) DE69232669T2 (de)
ES (1) ES2179824T3 (de)
MX (1) MX9207459A (de)
WO (1) WO1993013133A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5610194A (en) * 1992-11-16 1994-06-08 Centocor Inc. Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
PT725655E (pt) * 1993-11-05 2004-01-30 Centocor Inc Utilizacao de compostos capazes de se ligar a glicoproteina gpiib/iiia para a prevencao de estenose e de restenose
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
SK40599A3 (en) * 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CA2289910A1 (en) 1997-05-15 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for cachexia
WO1998055619A1 (de) * 1997-06-06 1998-12-10 Asat Ag Applied Science & Technology Anti-gpiib/iiia rekombinante antikörper
AU4314900A (en) * 1999-04-28 2000-11-17 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
EP1987842A1 (de) 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Zellproliferationshemmer
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.

Also Published As

Publication number Publication date
JP2723671B2 (ja) 1998-03-09
WO1993013133A1 (en) 1993-07-08
ES2179824T3 (es) 2003-02-01
ATE220100T1 (de) 2002-07-15
KR100240159B1 (ko) 2000-01-15
KR940703859A (ko) 1994-12-12
CA2126182A1 (en) 1993-07-08
MX9207459A (es) 1994-03-31
AU3095892A (en) 1993-07-28
EP0619324A1 (de) 1994-10-12
EP0619324A4 (en) 1995-11-29
DE69232669T2 (de) 2003-02-27
CA2126182C (en) 2001-07-17
EP0619324B1 (de) 2002-07-03

Similar Documents

Publication Publication Date Title
ES2108048T3 (es) Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE220100T1 (de) Mit gp11b/iiia reaktive humane antikörper
DK0652962T3 (da) Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
DK0502812T3 (da) Rekombinante antistoffer, som er specifikke for en vækstfaktorreceptor
ATE167896T1 (de) Aus mehreren domänen bestehende hämatopoese- stimulatoren
DK564989D0 (da) Bindingsproteiner
FI944509A (fi) Interferonireseptorin vastaisia monoklonaalisia vasta-aineita, joilla on neutralisoivaa aktiivisuutta tyypin I interferonia vastaan
ATE133200T1 (de) Modifiziertes, biologisch aktives protein
DK0407813T3 (da) Oxidativ denaturering af proteinanalytter
DE10299038I2 (de) Pl{ttchen-spezifisches Chim{risches immunglobulin.
NO175639C (no) Peptid, antistoff oppnådd ved hjelp av peptidet, en fremgangsmåte for immunologisk bestemmelse av intakt prokollagen peptid (type III) og anvendelse av peptidet
DK442888D0 (da) Slaegtspecifikt listeria-antigen identificeret ved hjaelp af monoklone antistoffer
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
DK329789D0 (da) Monoklonalt antistof
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
EP0603393A4 (de) Rekombinantes humanes interleukin-6 mit homogenem n-terminus und seine herstellung.
DE68913872D1 (de) Monoklonale Antikörper gegen den menschlichen Epidermal-Wachstumsfaktor mit hohem Molekulargewicht.
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP

Owner name: PROTEIN DESIGN LABS, INC., MOUNTAIN VIEW, CALIF.,

8339 Ceased/non-payment of the annual fee